BDBV is considered a less virulent Ebola virus due to itlower case fatality rate in human and animal outbreaks (25% to 51%). In contrast, the case fatality rate following Ebola virus infection in non-human primates is almost always fatal. While in-depth transcriptomic analyses have been conducted on samples from human patients and non-human primates infected with the Ebola virus, no such studies have been conducted on the Bundibugyo virus.
The clinical manifestations of Ebola virus infection in humans and non-human primates (NHPs) are similar and include viremia, cytokine storm and consumptive coagulopathy, which can lead to septic shock and multiple organ failure. The virus initially replicates in monocytes and dendritic cells before spreading to hepatocytes, endothelial cells and epithelial cells.
In May 2026, the World Health Organization (WHO) received a report of a highly fatal Bondibougio virus outbreak in Mongbwalu Health Zone, Ituri Province, Democratic Republic of the Congo (DRC), which resulted in deaths among healthcare workers. The Bondibougio virus forms filamentous viral particles and is closely related to the Zaire Ebola virus. It is one of several viruses that can cause Ebola in humans, presenting as viral haemorrhagic fever. Unlike Ebola virus disease, there are currently no approved vaccines or specific treatments for the Bondibougio virus, but early supportive care can save lives. This outbreak has once again drawn global attention to Ebola, highlighting the urgent need to develop effective diagnostic and preventive products.